These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31479408)

  • 21. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder.
    Jiang YH; Liao CH; Tang DL; Kuo HC
    PLoS One; 2014; 9(8):e105989. PubMed ID: 25148378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of onabotulinumtoxin A injection in male patients with detrusor overactivity after stress urinary incontinence surgery.
    Mateu-Arrom L; Gutiérrez-Ruiz C; Sabiote Rubio L; Martínez Barea V; Palou Redorta J; Errando-Smet C
    Actas Urol Esp (Engl Ed); 2022; 46(1):22-27. PubMed ID: 34838492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
    Wang CC; Lee CL; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome.
    Bauer RM; Gratzke C; Roosen A; Hocaoglu Y; Mayer ME; Buchner A; Stief CG; May F
    Urol Int; 2011; 86(1):68-72. PubMed ID: 20639617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population.
    Christiansen FE; Pedersen TB; Juel J; Kirkeby HJ
    Scand J Urol; 2017 Oct; 51(5):392-396. PubMed ID: 28699369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
    Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.
    Chermansky CJ; Richter HE; Jacoby K; Titanji W; Jenkins B; Geib T; Brucker BM
    J Urol; 2022 Oct; 208(4):855-862. PubMed ID: 35830550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
    Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
    Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.
    Rovner E; Kennelly M; Schulte-Baukloh H; Zhou J; Haag-Molkenteller C; Dasgupta P
    Neurourol Urodyn; 2011 Apr; 30(4):556-62. PubMed ID: 21351127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
    Jiang YH; Kuo HC
    Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: A scoping review.
    Kelsey E; Wynn J; Holmes A; McLeod K
    Neurourol Urodyn; 2024 Mar; 43(3):553-564. PubMed ID: 38225733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
    Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
    Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Committee opinion: onabotulinumtoxinA and the bladder.
    American Urogynecologic Society and American College of Obstetricians and Gynecologists
    Female Pelvic Med Reconstr Surg; 2014; 20(5):245-7. PubMed ID: 25181372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
    Lacout M; Guinet-Lacoste A; Popoff M; Verollet D; Lebreton F; Amarenco G
    Prog Urol; 2015 Sep; 25(11):642-8. PubMed ID: 26094097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?
    Miotla P; Cartwright R; Skorupska K; Bogusiewicz M; Markut-Miotla E; Futyma K; Rechberger T
    Int Urogynecol J; 2017 Jun; 28(6):845-850. PubMed ID: 27889830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intradetrusor onabotulinumtoxinA for overactive bladder.
    Jambusaria LH; Dmochowski RR
    Expert Opin Biol Ther; 2014 May; 14(5):721-7. PubMed ID: 24660999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intradetrusor onabotulinumtoxinA injection: how I do it.
    Shenot PJ; Mark JR
    Can J Urol; 2013 Feb; 20(1):6649-55; discussion 6655. PubMed ID: 23433140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.